A 2021 analysis of 78,500 individuals (Saez-Atienzar et al., Science Advances) used a polygenic-risk-score-based gene-set approach with human single-nucleus RNA-seq references to implicate neuron projection morphogenesis, membrane trafficking, and ribonucleotide-mediated signal transduction, and to map ALS genomic risk to GABAergic interneurons and oligodendrocytes. The authors explicitly framed what remains unresolved: the analysis was restricted to common (minor allele frequency ≥1%), intragenic variants of European-ancestry individuals with incomplete pathway databases; and oligodendrocyte enrichment did not replicate in the mouse brain reference, leaving the robustness of the cell-type assignments across references and species open. The open problem is a comprehensive determination of which biological pathways and CNS cell types carry ALS genetic risk once these restrictions are lifted — the contributions of rare, low-frequency, and intergenic regulatory variants to the implicated pathways and cell types; the additional pathway and cell-type signals that emerge in more extensive datasets; generalizability to non-European populations; the change in enrichments when pathway databases and single-cell references are extended; and whether the implicated cell-type assignments are robust across single-cell references and species. Literature 2021–2026 (van Rheenen et al. Nat Genet; RefMap; multi-ethnic and founder-population rare-variant collapsing studies; single-nucleus atlases) has extended the map at the gene and locus level but has not resolved any of these strands at the pathway or cell-type level, leaving the question open.

Background

Amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease of upper and lower motor neurons with a lifetime risk of roughly 1 in 350; about 10% of cases are familial with Mendelian inheritance (e.g., mutations in SOD1, C9orf72 repeat expansions), while most cases are sporadic. Twin studies estimate substantial heritability, yet genome-wide association studies (GWAS), which test common DNA variants across the genome for statistical association with disease, explain only a modest fraction of risk, consistent with ALS conforming largely to a rare-disease–rare-variant paradigm in which low-frequency variants contribute appreciably. Because individual common variants have small effects, a standard strategy is pathway (gene-set) analysis: variants are aggregated to genes, and genes to sets sharing a biological function (annotated in databases such as MSigDB, the Molecular Signatures Database), so that weak per-gene signals can emerge jointly. A complementary question is which cell types carry the genetic risk: gene-level association statistics are regressed against cell-type-specificity of expression measured in single-nucleus RNA-seq (snRNA-seq) atlases of human brain, which profile the transcriptome of individual nuclei (oligodendrocytes, astrocytes, microglia, and neuronal subtypes such as GABAergic interneurons — inhibitory cells using GABA as neurotransmitter — and glutamatergic excitatory neurons). Saez-Atienzar et al. (2021) combined 78,500 individuals in a three-stage polygenic-risk-score analysis (an approach that weights risk alleles by their estimated effects and aggregates them into per-pathway scores) with a newly generated human frontal-cortex snRNA-seq reference, additional human single-nucleus references (DroNc-seq prefrontal cortex and hippocampus; human primary motor cortex), and mouse single-cell datasets (brain and lumbar spinal cord). They identified three convergent pathway themes — neuron projection morphogenesis, membrane trafficking, and signal transduction mediated by ribonucleotides — and consistent genomic-risk enrichment in GABAergic interneurons and oligodendrocytes, and used Mendelian randomization (an instrumental-variable technique using genetic variants as instruments to infer causal effects of genetically regulated gene expression) to nominate six genes. The study's own Discussion states its boundaries: it analyzed only common variants (frequency ≥1%) within genes, in European-ancestry data, using pathway databases that incompletely capture neuronal and glial biology; and its Results report that oligodendrocyte enrichment did not replicate in the mouse brain reference, leaving the robustness of that assignment across references and species unresolved. A contemporaneous, even larger GWAS (van Rheenen et al. 2021; 29,612 cases) with whole-genome sequencing of 8,953 individuals prioritized genes at 15 risk loci and, using a different gene-property enrichment method, nominated glutamatergic neurons rather than GABAergic interneurons or oligodendrocytes — a method-dependent divergence reported by its authors as a stand-alone, concluded result, which remains background context indicating that the cell-type map of ALS risk is not settled. The unresolved scientific question is therefore the completion of this map: which pathways and cell types carry ALS genetic risk when rare, low-frequency, and intergenic regulatory variation, non-European populations, expanded pathway and single-cell references, and cross-species validation are brought into the analysis.

Problem Statement

Determine the biological pathways and central nervous system cell types through which genetic risk for amyotrophic lateral sclerosis acts, beyond the common-variant (minor allele frequency ≥1%), intragenic, European-ancestry scope of the Saez-Atienzar et al. (2021) analysis. The unresolved strands are: (1) the contribution of rare and low-frequency variants and of intergenic regulatory variants to ALS risk pathways and cell types — the direction for which the source anticipates that 'future analyses of more substantial datasets that include whole-genome sequencing data may implicate them'; (2) which additional pathways and cell types emerge as risk carriers when more extensive datasets become available; (3) how the pathway and cell-type enrichments change when pathway databases and single-cell expression references are extended to capture neuronal and glial biology more completely, including the periodic reevaluation the source motivates as more single-cell expression datasets become available; (4) whether the implicated pathway and cell-type enrichments generalize to non-European human populations; and (5) whether the genetically implicated cell-type assignments are robust across single-cell references and species, including the failure of oligodendrocyte enrichment to replicate in the mouse brain data. These five facets serve one overarching objective: a genotype-resolved, population-representative map of ALS risk pathways and cell types, in which the contributions of different variant frequency classes and regulatory versus coding action are explicitly partitioned. Because statistical power always bounds enumeration, the question is resolved by the field's own conventional standard — large-scale, ancestry-diverse pathway/cell-type analysis with replication, with a negative or inconclusive finding resolving it where power is limiting — rather than by an absolute exhaustive enumeration.

References

  1. Saez-Atienzar S, Bandres-Ciga S, Langston RG, Kim JJ, Choi SW, Reynolds RH, the International ALS Genomics Consortium, ITALSGEN, Abramzon Y, Dewan R, Ahmed S, Landers JE, Chia R, Ryten M, Cookson MR, Nalls MA, Chiò A, Traynor BJ. Genetic analysis of amyotrophic lateral sclerosis identifies contributing pathways and cell types. Science Advances 7(3):eabd9036, 2021. doi:10.1126/sciadv.abd9036, https://doi.org/10.1126/sciadv.abd9036 (source paper)
  2. van Rheenen W, van der Spek RAA, Bakker MK, van Vugt JJFA, Hop PJ, Zwamborn RAJ, de Klein N, Westra H-J, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics 53(12):1636-1648, 2021. doi:10.1038/s41588-021-00973-1, https://doi.org/10.1038/s41588-021-00973-1
  3. Vasilopoulou C, Duguez S, Duddy W. Genome-Wide Gene-Set Analysis Approaches in Amyotrophic Lateral Sclerosis. Journal of Personalized Medicine 12(11):1932, 2022. doi:10.3390/jpm12111932, https://doi.org/10.3390/jpm12111932
  4. Vasilopoulou C, McDaid-McCloskey SL, McCluskey G, Duguez S, Morris AP, Duddy W. Genome-Wide Gene-Set Analysis Identifies Molecular Mechanisms Associated with ALS. International Journal of Molecular Sciences 24(4):4021, 2023. doi:10.3390/ijms24044021, https://doi.org/10.3390/ijms24044021
  5. Zhang S, Cooper-Knock J, Weimer AK, et al. Genome-wide identification of the genetic basis of amyotrophic lateral sclerosis. Neuron 110(6):992-1008.e11, 2022. doi:10.1016/j.neuron.2021.12.019, https://doi.org/10.1016/j.neuron.2021.12.019 (RefMap)
  6. Limone F, Mordes DA, Couto A, Joseph BJ, Mitchell JM, Therrien M, Ghosh SD, Meyer D, Zhang Y, Goldman M, Bortolin L, Cobos I, Stevens B, McCarroll SA, Kadiu I, Burberry A, Pietiläinen O, Eggan K. Single-nucleus sequencing reveals enriched expression of genetic risk factors in extratelencephalic neurons sensitive to degeneration in ALS. Nature Aging 4(7):984-997, 2024. doi:10.1038/s43587-024-00640-0, https://doi.org/10.1038/s43587-024-00640-0
  7. Ross JP, Akçimen F, Liao C, Kwan K, Phillips DE, Schmilovich Z, Spiegelman D, Genge A, Dupré N, Dion PA, Farhan SMK, Rouleau GA. Rare-variant and polygenic analyses of amyotrophic lateral sclerosis in the French-Canadian genome. Genetics in Medicine 26(1):100967, 2024. doi:10.1016/j.gim.2023.100967, https://doi.org/10.1016/j.gim.2023.100967
  8. Pottinger TD, Motelow JE, Povysil G, et al. Rare variant analyses validate known ALS genes in a multi-ethnic population and identifies ANTXR2 as a candidate in PLS. BMC Genomics 25(1):651, 2024. doi:10.1186/s12864-024-10538-1, https://doi.org/10.1186/s12864-024-10538-1
  9. Moll T, Harvey C, Alhathli E, Gornall S, O'Brien D, Cooper-Knock J. Non-coding genome contribution to ALS. International Review of Neurobiology 176:75-86, 2024. doi:10.1016/bs.irn.2024.04.002, https://doi.org/10.1016/bs.irn.2024.04.002
  10. Nakamura R, Tohnai G, Nakatochi M, Atsuta N, Watanabe H, Ito D, et al. Genetic factors affecting survival in Japanese patients with sporadic amyotrophic lateral sclerosis: a genome-wide association study and verification in iPSC-derived motor neurons from patients. Journal of Neurology Neurosurgery and Psychiatry 94(10):816-824, 2023. doi:10.1136/jnnp-2022-330851, https://doi.org/10.1136/jnnp-2022-330851
  11. Yuan L, Yang Y, Guo Y, Deng H. Genetic architecture of amyotrophic lateral sclerosis: a comprehensive review. Journal of Genetics and Genomics 52(10):1155-1176, 2025. doi:10.1016/j.jgg.2025.05.008, https://doi.org/10.1016/j.jgg.2025.05.008
  12. Askarova A, Yaa RM, Marzi SJ, Nott A. Genetic risk for neurodegenerative conditions is linked to disease-specific microglial pathways. PLOS Genetics 21(4):e1011407, 2025. doi:10.1371/journal.pgen.1011407, https://doi.org/10.1371/journal.pgen.1011407